Iron isomaltoside

ApprovedSmall molecule

TThomas Jefferson University

Iron isomaltoside is one of 149 small molecule programs targeting Aortic Stenosis. It is currently in Approved.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic StenosisActive, not recruiting

HypophosphatemiaActive, not recruiting

AnemiaActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Colorectal CancerActive, not recruiting

Aortic StenosisPhase 2

Active, not recruiting

HypophosphatemiaApproved

Active, not recruiting

AnemiaApproved

Active, not recruiting

Inflammatory Bowel DiseaseApproved

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Iron isomaltoside

TThomas Jefferson University

Approved

3 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

Vascepa

1 5

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 6

Ketalar

AAultman Health Foundation

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Anemia

NCT07236788

Q4 2027

Post-ApprovalNot yet recruiting

Anemia

NCT06830941

Q1 2029

Phase 2Not yet recruiting

Colorectal Cancer

NCT05220800

Clinical

Trials by Indication[1]

Anemia5 trials

Intravenous Iron Infusion on Chemotherapy-induced Anemia

Unknown status·KKorea University Guro Hospital·Phase 2·NCT05299411·80 enrolled

Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients

Not yet recruiting·—·Phase 4·NCT06830941·124 enrolled

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Completed·UUniversity Medical Centre Ljubljana·Phase 3·NCT03957057·300 enrolled

Show 2 more trials

Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency.

Recruiting·—·N/A·NCT07236788·200 enrolled

Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial

Unknown status·YYonsei University·Phase 4·NCT03229954·358 enrolled

Colorectal Cancer3 trials

Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer

Not yet recruiting·ZZealand University Hospital·Phase 2·NCT05220800·134 enrolled

Effects of Preoperative Correction of Anemia With Intravenously Iron in Colorectal Cancer Patients.

Unknown status·ZZealand University Hospital·N/A·NCT05221957·200 enrolled

Efficacy of Preoperative Intravenous Iron in Anaemic Colorectal Cancer Surgical Patients

Completed·PPrince of Wales Hospital, Shatin, Hong Kong·Phase 3·NCT03565354·40 enrolled

Trial2 trials

RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study

Unknown status·TThomas Jefferson University··NCT05504863·538 enrolled

Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)

Completed·PPharmacosmos A/S·Phase 1·NCT03013439·24 enrolled

Hypophosphatemia1 trial

IV Iron-induced Hypophosphatemia After RYGB

Recruiting·LLucie Favre·Phase 4·NCT06350955·94 enrolled

Pregnancy1 trial

Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial

Completed·TThomas Jefferson University·Phase 4·NCT05358509·4,368 enrolled

6 more indications

Inflammatory Bowel Disease1 trial

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Completed·PPharmacosmos A/S·Phase 4·NCT03466983·97 enrolled

Neuroimaging1 trial

Neuroimaging Ancillary Study

Completed·TThomas Jefferson University··NCT05545527·184 enrolled

Peritoneal Dialysis1 trial

Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients

Terminated·TThe University of Hong Kong·N/A·NCT03610230·16 enrolled

Colorectal Surgery1 trial

Intravenous Iron for Correction of Anaemia After Colorectal Surgery

Unknown status·UUnknown Sponsor·Phase 4·NCT02999217·100 enrolled

Concentration1 trial

Effect of Preoperative Iron Isomaltoside 1000 Administration on Hemoglobin Concentration in Patients Undergoing Transcatheter Aortic Valve Implantation

Unknown status·YYonsei University·Phase 4·NCT04346004·214 enrolled

Aortic Stenosis1 trial

Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis

Unknown status·OOslo University Hospital·Phase 2·NCT04206228·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Iron isomaltoside. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iron isomaltoside compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iron isomaltoside. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thomas Jefferson University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThomas Jefferson University

Iron isomaltoside

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q1 2029

Trials by Indication[1]

Anemia5 trials

Colorectal Cancer3 trials

Trial2 trials

Hypophosphatemia1 trial

Pregnancy1 trial

Inflammatory Bowel Disease1 trial

Neuroimaging1 trial

Peritoneal Dialysis1 trial

Colorectal Surgery1 trial

Concentration1 trial

Aortic Stenosis1 trial

References

Drug Info

Quick Facts

Related News